ISRCTN06332944已完成不适用
Prevention of iatrogenic neurological impairment in schizophrenic disorders: the Schizophrenia Termination of Pharmacotherapy (STOP) trial
The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)0 个研究点目标入组 20 人开始时间: 2005年12月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent obtained after oral and written explanation to the patient and its doctor
- •2. Aged 16 to 55 years
- •3. Treated for at least a year, with antipsychotics, for a first episode of schizophrenia, schizoaffective disorder of schizophreniform disorder before inclusion
- •4. Diagnosis code 195.10, 295.20, 295.30, 295.60, 295.70 of 295.40 according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria as assessed at inclusion with the SCID (Structured Clinical Interview for DSM-IV)
- •5. The patient used antipsychotics for at least 335 days during the last year
- •6. All of the last year the patient was in a state of clinical remission, meant is that no clear symptoms of psychosis were observed, operationalised by the lack of a score of more then 3 on the following PANSS-items (Positive And Negative Syndrome Scale): Delusions (P1), Conceptual disorganisation (P2), Hallucinations (P3) and Suspicion (P6). Possibly there were still mild rest symptoms of which the patient experienced no hinder in daily functioning.
- •7. No serious physical disorder
- •8. No psychosis during inclusion, as operationalised under item 6
- •9. The patient has to be able to understand and undergo the trial procedures
排除标准
- •1. Judgment of the treating psychiatrist of the patient
- •2. The occurrence of a serious physical disease
- •3. Withdrawal of the informed consent of the patient
- •4. Death of the patient
研究者
相似试验
暂停
不适用
Schizophrenia Termination Of Pharmacotherapy-STOP-trial.Schizophrenic disorders:SchizophreniaSchizophreniform disorderSchizoaffective disorderNL-OMON26866Divisie Hersenen20
进行中（未招募）
1 期
Hydrocortisone as co-treatment to prevent neuropsychiatric adverse effects of dexamethasone.europsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance.EUCTR2017-003705-17-NLMC180
招募中
4 期
Prevention of neuropsychiatric adverse effects caused by dexamethasone: insights from a placebo-controlled trial with hydrocortisone.NL-OMON54782eids Universitair Medisch Centrum180
已完成
不适用
Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological HandicapsSeizuresEpilepsyNCT01459692Medical University of South Carolina40
招募中
不适用
Prevention of cerebral lesions by improving the management of postnatal hypoglycemia and hyperinsulinismP70.0P70.1P70.4P70.8P70.9E16.1Syndrome of infant of mother with gestational diabetesSyndrome of infant of a diabetic motherOther neonatal hypoglycaemiaOther transitory disorders of carbohydrate metabolism of fetus and newbornTransitory disorder of carbohydrate metabolism of fetus and newborn, unspecifiedOther hypoglycaemiaDRKS00021474niversitätsklinikum Düsseldorf200